Edward Nash
Stock Analyst at Canaccord Genuity
(4.12)
# 414
Out of 4,832 analysts
81
Total ratings
46.48%
Success rate
15.02%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Edward Nash
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $394 → $420 | $295.36 | +42.20% | 9 | May 2, 2025 | |
| CLDX Celldex Therapeutics | Initiates: Buy | $64 | $19.63 | +226.11% | 1 | Apr 28, 2025 | |
| TVTX Travere Therapeutics | Maintains: Buy | $45 → $47 | $20.94 | +124.45% | 10 | Apr 10, 2025 | |
| CORT Corcept Therapeutics | Maintains: Buy | $130 → $142 | $70.59 | +101.16% | 7 | Apr 1, 2025 | |
| RANI Rani Therapeutics Holdings | Maintains: Buy | $9 | $0.48 | +1,768.38% | 2 | Feb 26, 2025 | |
| VRNA Verona Pharma | Maintains: Buy | $44 → $72 | $67.57 | +6.56% | 9 | Feb 12, 2025 | |
| PLRX Pliant Therapeutics | Downgrades: Hold | $4 | $1.38 | +189.86% | 2 | Feb 10, 2025 | |
| AKRO Akero Therapeutics | Maintains: Buy | $56 → $73 | $40.01 | +82.45% | 6 | Jan 28, 2025 | |
| APGE Apogee Therapeutics | Initiates: Buy | $89 | $39.74 | +123.96% | 1 | Nov 25, 2024 | |
| VTYX Ventyx Biosciences | Maintains: Buy | $15 → $14 | $1.20 | +1,066.67% | 6 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $8 | $1.15 | +598.69% | 3 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $20 | $3.58 | +457.97% | 2 | Apr 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Hold | $8 | $2.62 | +205.34% | 4 | Jul 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $17 | $3.67 | +363.22% | 2 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $3 → $2 | $2.24 | -10.71% | 4 | May 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $900 → $180 | $1.29 | +13,853.49% | 2 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $82 | $35.40 | +131.64% | 6 | Jun 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $120 → $80 | $2.22 | +3,511.74% | 3 | Sep 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $48 | $12.81 | +274.71% | 1 | May 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $650 | $5.63 | +11,445.29% | 1 | Nov 8, 2017 |
Madrigal Pharmaceuticals
May 2, 2025
Maintains: Buy
Price Target: $394 → $420
Current: $295.36
Upside: +42.20%
Celldex Therapeutics
Apr 28, 2025
Initiates: Buy
Price Target: $64
Current: $19.63
Upside: +226.11%
Travere Therapeutics
Apr 10, 2025
Maintains: Buy
Price Target: $45 → $47
Current: $20.94
Upside: +124.45%
Corcept Therapeutics
Apr 1, 2025
Maintains: Buy
Price Target: $130 → $142
Current: $70.59
Upside: +101.16%
Rani Therapeutics Holdings
Feb 26, 2025
Maintains: Buy
Price Target: $9
Current: $0.48
Upside: +1,768.38%
Verona Pharma
Feb 12, 2025
Maintains: Buy
Price Target: $44 → $72
Current: $67.57
Upside: +6.56%
Pliant Therapeutics
Feb 10, 2025
Downgrades: Hold
Price Target: $4
Current: $1.38
Upside: +189.86%
Akero Therapeutics
Jan 28, 2025
Maintains: Buy
Price Target: $56 → $73
Current: $40.01
Upside: +82.45%
Apogee Therapeutics
Nov 25, 2024
Initiates: Buy
Price Target: $89
Current: $39.74
Upside: +123.96%
Ventyx Biosciences
Aug 12, 2024
Maintains: Buy
Price Target: $15 → $14
Current: $1.20
Upside: +1,066.67%
May 23, 2024
Maintains: Buy
Price Target: $6 → $8
Current: $1.15
Upside: +598.69%
Apr 8, 2024
Maintains: Buy
Price Target: $12 → $20
Current: $3.58
Upside: +457.97%
Jul 3, 2023
Assumes: Hold
Price Target: $8
Current: $2.62
Upside: +205.34%
May 19, 2023
Maintains: Buy
Price Target: $16 → $17
Current: $3.67
Upside: +363.22%
May 17, 2023
Maintains: Hold
Price Target: $3 → $2
Current: $2.24
Upside: -10.71%
Aug 8, 2022
Downgrades: Hold
Price Target: $900 → $180
Current: $1.29
Upside: +13,853.49%
Jun 19, 2020
Maintains: Buy
Price Target: $80 → $82
Current: $35.40
Upside: +131.64%
Sep 13, 2019
Maintains: Hold
Price Target: $120 → $80
Current: $2.22
Upside: +3,511.74%
May 24, 2018
Initiates: Buy
Price Target: $48
Current: $12.81
Upside: +274.71%
Nov 8, 2017
Initiates: Buy
Price Target: $650
Current: $5.63
Upside: +11,445.29%